- Home
- BRBI vs ETON Comparison
BRBI vs ETON Comparison
Compare BRBI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRBI | ETON |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Brazil | United States |
| Employees | 188 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 683.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BRBI | ETON |
|---|---|---|
| Price | $15.75 | $24.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 3.0K | ★ 471.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | $17.24 | $47.23 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $12.54 | $13.09 |
| 52 Week High | $67.01 | $27.29 |
Technical Indicators
Market Signals| Indicator | BRBI | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 54.47 |
| Support Level | $13.77 | $16.38 |
| Resistance Level | $15.63 | N/A |
| Average True Range (ATR) | 0.29 | 1.23 |
| MACD | 0.10 | -0.15 |
| Stochastic Oscillator | 57.14 | 40.16 |
Price Performance
Historical ComparisonAbout BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.